Sunshine Biopharma Inc.
SBFMDrugs in Pipeline
46
Phase 3 Programs
22
Upcoming Catalysts
11
Next Catalyst
This month
Market Overview
Stock performance and key metrics
11 upcoming, 0 past
611 Phase 3 Est. Readout
Estimated primary completion for 611 trial (NCT07042126) in Dermatitis, Atopic. Topline data typically follows completion by weeks to months.
Source10 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Mitizodone Phosphate tablets
Depressive Disorder, Major
Topical corticosteroid
Dermatitis, Atopic
608 Q2W
Psoriasis
Lerotinib
Esophageal Cancer
Clifutinib
Leukemia, Acute Myeloid (AML)
Pembrolizumab
Advanced Non-Small Cell Lung Cancer
611
Pulmonary Disease, Chronic Obstructive (COPD)
prefilled liquid etanercept(Yisaipu)
Ankylosing Spondylitis
Clascoterone
Acne Vulgaris
610
Asthma
SOF
Chronic HCV Infection
EPREX®
Renal Anemia
5% minoxidil foam
Androgenetic Alopecia
SSGJ-707
Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
HEC74647PA+HEC110114
Chronic HCV Infection
608 dose
Ankylosing Spondylitis
Insulin Degludec and Insulin Aspart
Diabetes
ranibizumab 0.5mg
Branch Retinal Vein Occlusion
601 1.25mg
Branch Retinal Vein Occlusion
DAG181
Chronic HCV Infection
HEC585
Idiopathic Pulmonary Fibrosis
Pirfenidone
Idiopathic Pulmonary Fibrosis (IPF)
HEC585 dose A
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
CT053PTSA
Non-small Cell Lung Cancer
Pemetrexed
First-line Advanced NSCLC Patients
RTV
Chronic Hepatitis B
Ranibizuman 0.5 mg
Central Retinal Vein Occlusion
Oxaliplatin
Metastatic Colorectal Cancer
HEC110114 Tablet
Chronic Hepatitis C
HEC169096
Advanced Solid Tumor
Clifutinib Besylate
Acute Myeloid Leukemia, Adult
SSGJ-705
Locally Advanced, Recurrent or Metastatic Malignancies
Injection of humanized nerve growth factor (NGF) antibody
Cancer Pain
SSGJ-706
First-line Advanced NSCLC Patients
GLS4
Chronic HBV Infection
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg
Gout Arthritis
Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)
Dermatitis, Atopic
HEC96719
Non-Alcoholic Steatohepatitis
608
Axial Spondyloarthritis
611 150mg
Dermatitis, Atopic
608 Dose A
Ankylosing Spondylitis
611 300 mg Q2W
Pulmonary Disease, Chronic Obstructive
Z650
Esophageal Squamous Cell Carcinoma
626
Systemic Lupus Erythematosus (SLE)
611 Q2W
Dermatitis, Atopic
SSS17
Anemia in Pre-Dialysis Patients
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mitizodone Phosphate tablets | Phase 3 | Depressive Disorder, Major | - | - |
Topical corticosteroid | Phase 3 | Dermatitis, Atopic | - | - |
608 Q2W | Phase 3 | Psoriasis | - | - |
Lerotinib | Phase 3 | Esophageal Cancer | - | - |
Clifutinib | Phase 3 | Leukemia, Acute Myeloid (AML) | - | - |
Pembrolizumab | Phase 3 | Advanced Non-Small Cell Lung Cancer | - | - |
611 | Phase 3 | Pulmonary Disease, Chronic Obstructive (COPD) | - | - |
prefilled liquid etanercept(Yisaipu) | Phase 3 | Ankylosing Spondylitis | - | - |
Clascoterone | Phase 3 | Acne Vulgaris | - | - |
610 | Phase 3 | Asthma | - | - |
SOF | Phase 3 | Chronic HCV Infection | - | - |
EPREX® | Phase 3 | Renal Anemia | - | - |
5% minoxidil foam | Phase 3 | Androgenetic Alopecia | - | - |
SSGJ-707 | Phase 3 | Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer | - | - |
HEC74647PA+HEC110114 | Phase 3 | Chronic HCV Infection | - | - |
608 dose | Phase 3 | Ankylosing Spondylitis | - | - |
Insulin Degludec and Insulin Aspart | Phase 3 | Diabetes | - | - |
ranibizumab 0.5mg | Phase 3 | Branch Retinal Vein Occlusion | - | - |
601 1.25mg | Phase 3 | Branch Retinal Vein Occlusion | - | - |
DAG181 | Phase 3 | Chronic HCV Infection | - | - |
HEC585 | Phase 3 | Idiopathic Pulmonary Fibrosis | - | - |
Pirfenidone | Phase 3 | Idiopathic Pulmonary Fibrosis (IPF) | - | - |
HEC585 dose A | Phase 2 | Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) | - | - |
CT053PTSA | Phase 2 | Non-small Cell Lung Cancer | - | - |
Pemetrexed | Phase 2 | First-line Advanced NSCLC Patients | - | - |
RTV | Phase 2 | Chronic Hepatitis B | - | - |
Ranibizuman 0.5 mg | Phase 2 | Central Retinal Vein Occlusion | - | - |
Oxaliplatin | Phase 2 | Metastatic Colorectal Cancer | - | - |
HEC110114 Tablet | Phase 2 | Chronic Hepatitis C | - | - |
HEC169096 | Phase 2 | Advanced Solid Tumor | - | - |
Clifutinib Besylate | Phase 2 | Acute Myeloid Leukemia, Adult | - | - |
SSGJ-705 | Phase 2 | Locally Advanced, Recurrent or Metastatic Malignancies | - | - |
Injection of humanized nerve growth factor (NGF) antibody | Phase 2 | Cancer Pain | - | - |
SSGJ-706 | Phase 2 | First-line Advanced NSCLC Patients | - | - |
GLS4 | Phase 2 | Chronic HBV Infection | - | - |
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg | Phase 2 | Gout Arthritis | - | - |
Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) | Phase 2 | Dermatitis, Atopic | - | - |
HEC96719 | Phase 2 | Non-Alcoholic Steatohepatitis | - | - |
608 | Phase 2 | Axial Spondyloarthritis | - | - |
611 150mg | Phase 2 | Dermatitis, Atopic | - | - |
608 Dose A | Phase 2 | Ankylosing Spondylitis | - | - |
611 300 mg Q2W | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Z650 | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
626 | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
611 Q2W | Phase 2 | Dermatitis, Atopic | - | - |
SSS17 | Phase 2 | Anemia in Pre-Dialysis Patients | - | - |